The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior

International Journal of Molecular Sciences

Volumn 13, Issue 1, 2012, Pages 1109-1125

  Zhang, Dongyong ^a   Tian, Ang ^b   Xue, Xiangxin ^b   Wang, Mei ^b   Qiu, Bo ^a   Wu, Anhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NORTHEASTERN UNIVERSITY   (China)

Author keywords

Controlled release; Glioma; Hydroxyapatite; Poly (lactide co glycolide) PLGA; Temozolomide (TMZ)

Indexed keywords

MICROSPHERE; POLYGLACTIN; TEMOZOLOMIDE; VITRONECTIN RECEPTOR; ALKYLATING AGENT; DACARBAZINE; DRUG CARRIER; HYDROXYAPATITE; LACTIC ACID; NANOMATERIAL; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFICACY; DRUG RELEASE; ENZYME INHIBITION; GLIOMA CELL; HUMAN; HUMAN CELL; NANOFABRICATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; WESTERN BLOTTING; X RAY DIFFRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; GLIOMA; METABOLISM; PATHOLOGY; TOXICITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DRUG CARRIERS; DURAPATITE; GLIOMA; HUMANS; INTEGRIN ALPHAVBETA3; LACTIC ACID; MICROSPHERES; NANOSTRUCTURES; POLYGLYCOLIC ACID;

EID: 84863037728     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13011109     Document Type: Article

References (28)

1. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
2. Mason, W.P.; Cairncross, J.G. Drug insight: Temozolomide as a treatment for malignant glioma-Impact of a recent trial. Nat. Clin. Pract. Neurol. 2005, 1, 88-95.
3. Baker, S.D.; Wirth, M.; Statkevich, P.; Reidenberg, P.; Alton, K.; Sartorius, S.E.; Dugan, M.; Cutler, D.; Batra, V.; Grochow, L.B.; et al. Absorption, metabolism, and excretion of 14c-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 1999, 5, 309-317.
4. Chakravarti, A.; Erkkinen, M.G.; Nestler, U.; Stupp, R.; Mehta, M.; Aldape, K.; Gilbert, M.R.; Black, P.M.; Loeffler, J.S. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin. Cancer Res. 2006, 12, 4738-4746.
5. Zhang, H.; Gao, S. Temozolomide/plga microparticles and antitumor activity against glioma c6 cancer cells in vitro. Int. J. Pharm. 2007, 329, 122-128.
6. Zhang, Y.H.; Yue, Z.J.; Zhang, H.; Tang, G.S.; Wang, Y.; Liu, J.M. Temozolomide/plga microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. Eur. J. Pharm. Biopharm. 2010, 76, 371-375.
7. Yang, Z.J.; Best, S.M.; Cameron, R.E. The influence of α-tricalcium phosphate nanoparticles and microparticles on the degradation of poly(d,l-lactide-co-glycolide). Adv. Mater. 2009, 21, 3900-3904.
8. Wei, G.; Ma, P.X. Partially nanofibrous architecture of 3d tissue engineering scaffolds. Biomaterials 2009, 30, 6426-6434.
9. Xue, J.M.; Shi, M. Plga/mesoporous silica hybrid structure for controlled drug release. J. Control. Release 2004, 98, 209-217.
10. Ara, M.; Watanabe, M.; Imai, Y. Effect of blending calcium compounds on hydrolytic degradation of poly(dl-lactic acid-co-glycolic acid). Biomaterials 2002, 23, 2479-2483.
11. Ho, M.L.; Fu, Y.C.; Wang, G.J.; Chen, H.T.; Chang, J.K.; Tsai, T.H.; Wang, C.K. Controlled release carrier of bsa made by w/o/w emulsion method containing plga and hydroxyapatite. J. Control. Release 2008, 128, 142-148.
12. Xu, Q.; Tanaka, Y.; Czernuszka, J.T. Encapsulation and release of a hydrophobic drug from hydroxyapatite coated liposomes. Biomaterials 2007, 28, 2687-2694.
13. Yang, P.; Quan, Z.; Li, C.; Kang, X.; Lian, H.; Lin, J. Bioactive, luminescent and mesoporous europium-doped hydroxyapatite as a drug carrier. Biomaterials 2008, 29, 4341-4347.
14. Liu, T.Y.; Chen, S.Y.; Liu, D.M.; Liou, S.C. On the study of bsa-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery. J. Control. Release 2005, 107, 112-121.
15. Nie, H.; Wang, C.H. Fabrication and characterization of plga/hap composite scaffolds for delivery of bmp-2 plasmid DNA. J. Control. Release 2007, 120, 111-121.
16. Shi, X.; Wang, Y.; Ren, L.; Gong, Y.; Wang, D.A. Enhancing alendronate release from a novel plga/hydroxyapatite microspheric system for bone repairing applications. Pharm. Res. 2009, 26, 422-430.
17. Shen, H.; Hu, X.; Yang, F.; Bei, J.; Wang, S. An injectable scaffold: Rhbmp-2-loaded poly (lactide-co-glycolide)/hydroxyapatite composite microspheres. Acta Biomater. 2010, 6, 455-465.
18. Okada, M.; Furukawa, K.; Serizawa, T.; Yanagisawa, Y.; Tanaka, H.; Kawai, T.; Furuzono, T. Interfacial interactions between calcined hydroxyapatite nanocrystals and substrates. Langmuir 2009, 25, 6300-6306.
19. Tian, A.; Wang, C.; Xue, X.; Wu, A.; Guan, G.; Wang, L.; Qiu, B. Inhibitory effect of nano-ha particles on human u87 glioblastoma cells viability. J. Inorg. Mater. 2010, 25, 101-106.
20. Bodmeier, R.; Chen, H. Preparation and characterization of microspheres containing the anti-inflammatory agents, indomethacin, ibuprofen, and ketoprofen. J. Control. Release 1989, 10, 167-175.
21. Liu, J.J.; Lin, M.; Yu, J.Y.; Liu, B.; Bao, J.K. Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett. 2011, 300, 105-114.
22. Bello, L.; Lucini, V.; Giussani, C.; Carrabba, G.; Pluderi, M.; Scaglione, F.; Tomei, G.; Villani, R.; Black, P.M.; Bikfalvi, A.; et al. Is20i, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery 2003, 52, 177-186.
23. Hood, J.D.; Cheresh, D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2, 91-100.
24. Bello, L.; Francolini, M.; Marthyn, P.; Zhang, J.; Carroll, R.S.; Nikas, D.C.; Strasser, J.F.; Villani, R.; Cheresh, D.A.; Black, P.M. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001, 49, 380-390.
25. D'Abaco, G.M.; Kaye, A.H. Integrins: Molecular determinants of glioma invasion. J. Clin. Neurosci. 2007, 14, 1041-1048.
26. Deryugina, E.I.; Bourdon, M.A.; Luo, G.X.; Reisfeld, R.A.; Strongin, A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J. Cell Sci. 1997, 110, 2473-2482.
27. Cai, Y.; Liu, Y.; Yan, W.; Hu, Q.; Tao, J.; Zhang, M.; Shi, Z.; Tang, R. Role of hydroxyapatite nanoparticle size in bone cell proliferation. J. Mater. Chem. 2007, 17, 3780-3787.
28. Guo, X.; Gough, J.E.; Xiao, P.; Liu, J.; Shen, Z. Fabrication of nanostructured hydroxyapatite and analysis of human osteoblastic cellular response. J. Biomed. Mater. Res. A 2007, 82, 1022-1032.